Pharmaceuticals

Viva Biotech Partnership Summit Successfully Launched in Shanghai

SHANGHAI, Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on8 November 2019 in Pudong, Shanghai, themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies incubated/ invested by Viva ...

2019-11-15 14:16 2279

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that Natio...

2019-11-14 23:45 1118

Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO

INCHEON, South Korea, Nov. 14, 2019 /PRNewswire/ -- Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally. A ceremony...

2019-11-14 20:00 1375

MeMed Wins €2.5M Award from European Innovation Council

Funding to Accelerate Launch of MeMed's Point-of-Care Platform that Distinguishes Between Bacterial and Viral Infections,Enabling More Prompt, Well-Informed Antimicrobial Treatment Decisions HAIFA, Israel, Nov. 13, 2019 /PRNewswire/ -- MeMed Ltd. , a leader in host respo...

2019-11-14 09:00 2125

China Biologic Reports Financial Results for the Third Quarter of 2019

BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2019. Third Quarter...

2019-11-14 05:43 6391

Merck Licenses CRISPR Gene-Editing Technology to Evotec

-- License to accelerate research, enable testing and development of new drugs DARMSTADT, Germany, Nov. 12, 2019 /PRNewswire/ -- Merck, a leading science and technology company, today announced that it has signed a license agreement providingEvotec SE access to Merck's foundational CRISPR intelle...

2019-11-12 21:00 2226

ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders

BERLIN and TORONTO, Nov. 11, 2019 /PRNewswire/ -- ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, andCyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery proce...

2019-11-11 21:45 1257

Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting

NATIONAL HARBOR, Md., Nov. 11, 2019 /PRNewswire/ -- Akeso Biopharma ("Akeso") presented results of phase 1 study of its first-in-class bispecific drug candidate  AK104, in patients with advanced solid tumors in 2019 Society for Immunotherapy of Cancer ("SITC"). AK104 is a novel, tetrameric bispec...

2019-11-11 17:35 2307

Akeso, Inc. Completes Series-D Private Financing for US$150 Million

ZHONGSHAN, China, Nov. 9, 2019 /PRNewswire/ -- Akeso, Inc. (hereinafter referred to as "Akeso") announced the completion of its Series-D private financing for nearlyUS$150 million, which was co-led in investment by Loyal Valley Capital ("LVC") and Sino Biopharmaceutical Co. Ltd. ("Sino Biopharm")...

2019-11-09 00:43 3011

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

MADISON, Wisconsin, Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed itspreviously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics co...

2019-11-08 21:24 6875

Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial

Not intended for US, Canada and UK-based media  DARMSTADT, Germany, and NEW YORK, Nov. 8, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction ch...

2019-11-08 21:00 5954

SINOCHEM PHARMACEUTICAL Participated in CPhI Worldwide Europe

FRANKFURT, Germany, Nov. 8, 2019 /PRNewswire/ -- From November 5 to 7, 2019, CPhI Worldwide Europe was held in the Exhibition CentreFrankfurt, Germany. Dong Jianhua, executive director of Sinochem Pharmaceutical Co., Ltd., led a delegation to attend the exhibition. Sinochem Pharmaceutical has be...

2019-11-08 17:36 2660

Omega-3 Fatty-acid Enriched Parenteral Nutrition Improves Patient Outcomes

BAD HOMBURG, Germany, Nov. 8, 2019 /PRNewswire/ -- A new systematic literature review and meta-analysis[1] confirms and extends previous results that omega-3 (ω-3) fatty-acid enriched parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients. Including a tot...

2019-11-08 11:00 2563

Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost

PUNE, India, Nov. 7, 2019 /PRNewswire/ -- Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The s...

2019-11-07 21:02 1612

Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost

PUNE, India, Nov. 7, 2019 /PRNewswire/ -- Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The s...

2019-11-07 20:24 1569

TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma

NANJING, China, Nov. 7, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu, Founde...

2019-11-07 20:08 1168

TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million

HONG KONG, Nov. 7, 2019 /PRNewswire/ -- A clinical-stage biopharmaceutical company with full industry value chain capabilities, TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company", together with its subsidiaries, the "Group", stock code: 1875) was well received by the capi...

2019-11-07 19:04 6930

Bactiguard Holding AB (publ): Interim Report for Q3 2019

STOCKHOLM, Nov. 7, 2019 /PRNewswire/ -- The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactigua...

2019-11-07 15:23 6499

ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Nov. 7, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that an abstract on the CS1001-201 trial (Abstract #2833) was accepted by the 2019 American Society of Hematology (ASH) Annual Meeting and has been published online yesterday...

2019-11-07 11:02 2450

Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

- Bioeq agreement brings promise of their leading Lucentis® biosimilar for the treatment of retinopathies one step nearer for U.S. patients - ZÜRICH, Nov. 7, 2019 /PRNewswire/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, In...

2019-11-07 05:14 2218
1 ... 300301302303304305306 ... 308